(Q24240015)

30 June 2019

meta-analysis

0 references

review article

1 reference

title

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women (English)

1 reference

30 June 2019

1 reference

Jane Beith

4

0 references

author name string

Shom Goel

series ordinal

1

1 reference

30 June 2019

Rohini Sharma

series ordinal

2

1 reference

30 June 2019

Anne Hamilton

series ordinal

3

1 reference

30 June 2019

publication date

7 October 2009

1 reference

30 June 2019

Cochrane Database of Systematic Reviews

published in

1 reference

30 June 2019

issue

4

1 reference

30 June 2019

page(s)

CD004562

1 reference

30 June 2019

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Ovarian ablation for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004562.PUB4

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 r

21 January 2018

1 reference

12 December 2020

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast canc

1 reference

12 December 2020

Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B

1 reference

12 December 2020

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study

1 reference

12 December 2020

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial

1 reference

12 December 2020

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)

1 reference

12 December 2020

Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer

1 reference

12 December 2020

Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex

1 reference

12 December 2020

Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London

1 reference

12 December 2020

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study

1 reference

12 December 2020

Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause

1 reference

12 December 2020

10.1002/14651858.CD004562.PUB4

Identifiers

DOI

1 reference

30 June 2019

OpenCitations bibliographic resource ID

1365291

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

30 June 2019

PubMed publication ID

19821328

1 reference

30 June 2019